Recent advances in the development of NS5B polymerase inhibitors for the treatment of hepatitis C virus infection

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

(2008) W. Yang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

(2008) A. Y. M. Howe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Novel HCV NS5B polymerase inhibitors derived from 4-(1′,1′-dioxo-1′,4′-dihydro-1′λ6-benzo[1′,2′,4′]thiadiazin-3′-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties

(2008) Maria V. Sergeeva et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Des-A-ring benzothiadiazines: Inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase

(2008) Pamela L. Donner et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Early steps of the hepatitis C virus life cycle

(2008) Jean Dubuisson et al.   CELLULAR MICROBIOLOGY

The emerging field of HCV drug resistance

(2008) Gennadiy Koev et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin

(2008) Paul J. Pockros et al.   HEPATOLOGY

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C

(2008) Stuart K. Roberts et al.   HEPATOLOGY

Synthesis and SAR of novel 1,1-dialkyl-2(1H)-naphthalenones as potent HCV polymerase inhibitors

(2007) Todd D. Bosse et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS